Alzamend Neuro Company Leadership
| ALZN Stock | USD 1.31 0.01 0.77% |
Alzamend Neuro's insiders are aggressively buying. The analysis of the overall insider sentiment regarding Alzamend Neuro suggests that virtually all insiders are extremely bullish. Alzamend Neuro employs about 4 people. The company is managed by 5 executives with a total tenure of roughly 10 years, averaging almost 2.0 years of service per executive, having 0.8 employees per reported executive.
Alzamend Neuro's Insider Buying Vs Selling
100
Selling | Buying |
Latest Trades
| 2024-08-06 | Milton C Ault III | Acquired 75 @ 2.75 | View | ||
| 2024-07-31 | Milton C Ault III | Acquired 25 @ 3.74 | View | ||
| 2024-04-19 | Milton C Ault III | Acquired 100 @ 6.9 | View | ||
| 2024-04-01 | Milton C Ault III | Acquired 33 @ 9.1 | View | ||
| 2024-01-05 | Milton C Ault III | Acquired 500 @ 10.2 | View | ||
| 2023-12-26 | Milton C Ault III | Acquired 50 @ 9 | View | ||
| 2023-12-22 | Milton C Ault III | Acquired 20 @ 9.2 | View |
Monitoring Alzamend Neuro's insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Alzamend |
Alzamend Neuro Management Team Effectiveness
The company has return on total asset (ROA) of (2.1447) % which means that it has lost $2.1447 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (44.0831) %, meaning that it created substantial loss on money invested by shareholders. Alzamend Neuro's management efficiency ratios could be used to measure how well Alzamend Neuro manages its routine affairs as well as how well it operates its assets and liabilities. As of the 23rd of November 2024, Return On Tangible Assets is likely to grow to -14.96. In addition to that, Return On Capital Employed is likely to drop to 3.64. As of the 23rd of November 2024, Debt To Assets is likely to grow to 0.95, while Net Tangible Assets are likely to drop about 3.3 M.As of the 23rd of November 2024, Common Stock Shares Outstanding is likely to drop to about 642.7 K. In addition to that, Net Loss is likely to grow to about (12.7 M)
Alzamend Neuro Workforce Comparison
Alzamend Neuro is rated below average in number of employees category among its peers. The total workforce of Health Care industry is presently estimated at about 503. Alzamend Neuro maintains roughly 4.0 in number of employees contributing less than 1% to equities under Health Care industry.
Alzamend Neuro Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Alzamend Neuro insiders, such as employees or executives, is commonly permitted as long as it does not rely on Alzamend Neuro's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Alzamend Neuro insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Alzamend Neuro Notable Stakeholders
An Alzamend Neuro stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Alzamend Neuro often face trade-offs trying to please all of them. Alzamend Neuro's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Alzamend Neuro's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Milton III | Founder Chairman | Profile | |
| Henry Esq | General VP | Profile | |
| Kenneth CPA | Senior Finance | Profile | |
| David Katzoff | Chief Officer | Profile | |
| Stephan Jackman | CEO Director | Profile |
About Alzamend Neuro Management Performance
The success or failure of an entity such as Alzamend Neuro often depends on how effective the management is. Alzamend Neuro management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Alzamend management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Alzamend management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (15.75) | (14.96) | |
| Return On Capital Employed | 3.83 | 3.64 | |
| Return On Assets | (15.75) | (14.96) | |
| Return On Equity | 3.83 | 3.64 |
Alzamend Neuro Workforce Analysis
Traditionally, organizations such as Alzamend Neuro use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Alzamend Neuro within its industry.Alzamend Neuro Manpower Efficiency
Return on Alzamend Neuro Manpower
| Revenue Per Employee | 0.0 | |
| Revenue Per Executive | 0.0 | |
| Net Loss Per Employee | 2.5M | |
| Net Loss Per Executive | 2M |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Alzamend Neuro. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. To learn how to invest in Alzamend Stock, please use our How to Invest in Alzamend Neuro guide.You can also try the Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Alzamend Neuro. If investors know Alzamend will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Alzamend Neuro listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (142.87) | Return On Assets (2.14) | Return On Equity (44.08) |
The market value of Alzamend Neuro is measured differently than its book value, which is the value of Alzamend that is recorded on the company's balance sheet. Investors also form their own opinion of Alzamend Neuro's value that differs from its market value or its book value, called intrinsic value, which is Alzamend Neuro's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Alzamend Neuro's market value can be influenced by many factors that don't directly affect Alzamend Neuro's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Alzamend Neuro's value and its price as these two are different measures arrived at by different means. Investors typically determine if Alzamend Neuro is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Alzamend Neuro's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.